Ronald W. Takvorian

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Philipp Karschnia, Justin T. Jordan, Deborah Forst et al. · Blood · 2019 · 329 citations · Full text

Primary Pulmonary Lymphoma

Brian B. Graham, Douglas J. Mathisen, Eugene J. Mark et al. · The Annals of Thoracic Surgery · 2005 · 108 citations · Full text

Lymphoid Neoplasia, Pathology, Primary Pulmonary Lymphoma +4

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

Jacob D. Soumerai, Matthew D. Hellmann, Yang Feng et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 84 citations

Lymphoid Neoplasia, Optimal Therapy, Radiation Therapy +13

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

Jennifer R. Brown, Jonathan W. Friedberg, Yang Feng et al. · British Journal of Haematology · 2009 · 78 citations · Full text

Surgical Oncology, Immunology, Pathology +16

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Matthew S. Davids, Danielle M. Brander, Haesook T. Kim et al. · The Lancet Haematology · 2019 · 70 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia +11